In this study, we probe and verify the concept of designing unreactive bioactive metal complexes, in which the metal possesses a purely structural function, by investigating the consequences of replacing ruthenium in a bioactive half-sandwich kinase inhibitor scaffold by its heavier congener osmium. The two isostructural complexes are compared with respect to their anticancer properties in 1205 Lu melanoma cells, activation of the Wnt signaling pathway, IC(50) values against the protein kinases GSK-3beta and Pim-1, and binding modes to the protein kinase Pim-1 by protein crystallography. It was found that the two congeners display almost indistinguishable biological activities, which can be explained by their nearly identical three-dimensio...
Ruthenium anticancer drugs have attracted an increasing interest in the last 20 years and two of the...
Mammalian sterile 20 (MST1) kinase, a member of the sterile 20 (Ste-20) family of proteins, is a pro...
Ruthenium-based anticancer chemotherapies are making significant advances in clinical trials. Until ...
In this study, we probe and verify the concept of designing unreactive bioactive metal complexes, in...
Tightly controlled by the action of protein kinases, protein phosphorylation regulates most aspects ...
The design and synthesis of selective small molecule inhibitors of protein kinases to modulate their...
(1) Background: Ruthenium and osmium complexes attract increasing interest as next generation antica...
The vast majority of metals currently used in medicine take advantage of the reactivity of the metal...
International audienceMetal complexes have been used to treat cancer since the discovery of cisplati...
Ruthenium complexes are developed as substitutes for platinum complexes to be used in the chemothera...
Half sandwich organometal complexes of Ru(II), Os(II), Rh(III) and Ir(III) with -diketone-like liga...
International audienceThe identification of the mode of action of a drug is mandatory for the develo...
Background\ud An arene ruthenium(II) complex containing neutral ligands and monoanionic nitrogen don...
We have compared the organometallic arene complexes [(eta(6)-biphenyl)M(ethylenediamine)Cl](+) RM175...
Countless expectations converge in the multidisciplinary endeavour for the search and development of...
Ruthenium anticancer drugs have attracted an increasing interest in the last 20 years and two of the...
Mammalian sterile 20 (MST1) kinase, a member of the sterile 20 (Ste-20) family of proteins, is a pro...
Ruthenium-based anticancer chemotherapies are making significant advances in clinical trials. Until ...
In this study, we probe and verify the concept of designing unreactive bioactive metal complexes, in...
Tightly controlled by the action of protein kinases, protein phosphorylation regulates most aspects ...
The design and synthesis of selective small molecule inhibitors of protein kinases to modulate their...
(1) Background: Ruthenium and osmium complexes attract increasing interest as next generation antica...
The vast majority of metals currently used in medicine take advantage of the reactivity of the metal...
International audienceMetal complexes have been used to treat cancer since the discovery of cisplati...
Ruthenium complexes are developed as substitutes for platinum complexes to be used in the chemothera...
Half sandwich organometal complexes of Ru(II), Os(II), Rh(III) and Ir(III) with -diketone-like liga...
International audienceThe identification of the mode of action of a drug is mandatory for the develo...
Background\ud An arene ruthenium(II) complex containing neutral ligands and monoanionic nitrogen don...
We have compared the organometallic arene complexes [(eta(6)-biphenyl)M(ethylenediamine)Cl](+) RM175...
Countless expectations converge in the multidisciplinary endeavour for the search and development of...
Ruthenium anticancer drugs have attracted an increasing interest in the last 20 years and two of the...
Mammalian sterile 20 (MST1) kinase, a member of the sterile 20 (Ste-20) family of proteins, is a pro...
Ruthenium-based anticancer chemotherapies are making significant advances in clinical trials. Until ...